The Biosimilar Development Industry 2018 Featuring: Amgen, Celltrion, Pfizer, Samsung Bioepis, and Sandoz-Novartis - ResearchAndMarkets.com

October 1, 2018

DUBLIN--(BUSINESS WIRE)--Oct 1, 2018--The “Biosimilar Development Industry” report has been added to ResearchAndMarkets.com’s offering.

The report provides a deep insight of the Biosimilar Development Industry and helps understand its outpacing growth and acceptability over original biologics in different regions.

It helps to analyse the Biosimilar market by gaining knowledge on Regulations in different regions, supply-demand factors, revenue and cost drivers, challenges along with current approval of biosimilars by US-FDA and EU-EMA and analysis of porter five forces.

The report gives extra emphasis on the Korean Biosimilar Development Industry and help analyse its current market scenario, favourable market dynamics, challenges and key partnerships by local players. Additionally, a comparison of key players along with their product pipeline, operational and financial summary has been provided.

Companies Featured

Amgen Celltrion Pfizer Samsung Bioepis Sandoz-Novartis

Key Topics Covered

1. Introduction to Biosimilar

Biologics vs Biosimilars

2. Global Biosimilars Market Overview

3. Regulation of Biosimilar Region Wise

4. Porter’s - Five Forces Analysis

Bargaining Power of Suppliers Bargaining Power of Buyers Barriers to Entry Threat of Substitutes Competition

5. Supply and Demand

6. Patents - Approvals, Expiry, Pipeline

Biosimilar Approved in The USA Biosimilar Approved in EU Major Biosimilar Players’ Pipeline Drugs

7. Key Revenue and Cost Drivers

Biologics Patent Expiration Lower Cost Increase Patient Access Increase in Rate of Chronic Diseases Patient Awareness and Physicians Support Geographic Penetration Research and Development Cost Complex Manufacturing Process Regulatory Process Government Support

8. Restraints and Challenges in Biosimilar Industry

Substitution and Interchangeability Biobetters Production Complexity Regulatory Process Brand Consciousness

9. South Korean Biosimilar Market

Current Market Scenario Favourable Market Dynamics Challenges for Biosimilar Development in Korea Agreement and Partnership for Development of Biosimilars in Korea

10. Key Players in Biosimilar Industry

For more information about this report visit https://www.researchandmarkets.com/research/dqgb3n/the_biosimilar?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005521/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biosimilars and Biosuperiors



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/01/2018 08:36 AM/DISC: 10/01/2018 08:36 AM


Update hourly